Biotech Values

[spartex]

Dew, yes good calls by you regarding your predictions!

The only thing that most people who were bearish (or neutral) on DNDN didn't expect was the stock to be trading at 50% premium to the pre-panel meeting after a follow-up "approvable" letter by the FDA. Even I, being bullish on the cassette immunotherapy concept, but cautious in my expectations of DNDN's chances w/ FDA, didn't expect the stock to be much higher than $5 initially. However, I believe there are a number of positive things going on behind the scenes (discussed on the conf call) than just the anticipated update on 9902b trial enrollment being complete/announced, and then interim data release by DNDN next year. I see downside of around $4-5 bucks if DNDN misses their "supportive interim" update w/ FDA, while upside of $18++ if they provide what the FDA needs for approval. I like this bet, especially since my current avg. position is in the low $5's. I can wait it out without much worry.